Navigation Links
USGI Medical Licenses Incisionless Surgery Technology to Intuitive Surgical
Date:5/12/2008

SAN CLEMENTE, Calif., May 12 /PRNewswire/ -- USGI Medical, Inc. (USGI), the leader in incisionless surgery, announced today that the company has licensed its incisionless surgery technology to Intuitive Surgical (Nasdaq: ISRG) for use in medical robotics applications. Financial terms of the deal were not disclosed.

"We've been impressed by USGI's technical and clinical development including their intellectual property," said Gary Guthart, president and chief operating officer of Intuitive Surgical Inc. "The combination of USGI's intellectual property with Intuitive's robotic capabilities allows for compelling possibilities for future robotic products."

USGI's incisionless surgery platform, the EndoSurgical Operating System(TM) (EOS), is designed to address a wide range of surgical indications. Surgeons and gastroenterologists currently use the EOS to perform endolumenal (procedures within the GI tract) and translumenal procedures through the body's natural orifices (these are commonly referred to as "NOTES" or Natural Orifice Translumenal Endoscopic Surgery). Eliminating skin incisions may reduce the risk of infection and associated complications and may result in less post-operative pain, faster recovery time and no abdominal scars for patients.

"This agreement with Intuitive Surgical is another step forward in our efforts to establish the EOS as the leading, most complete surgical platform for Incisonless Surgery," said USGI Medical CEO Eugene Chen. "Many of the country's leading physicians have used the EOS to complete a wide range of groundbreaking incisionless procedures. We believe that mechanical and robotic solutions complement each other and together will advance and expand this field to a wider group of procedures and patients."

Surgeons have used USGI's EOS to complete the first transgastric gall bladder and appendix removals in the U.S. and to close the access incision (gastrotomy) in the stomach wall during NOTES procedures. Many surgeons and gastroenterologists use the EOS routinely to perform an incisionless procedure to reduce the size of the gastric pouch and stoma in patients who experience weight regain after gastric bypass surgery.

About USGI Medical

USGI Medical is the leader in Incisionless Surgery. USGI's EndoSurgical Operating System(TM) (EOS) provides surgeons the operating platform and specialized tools they need to perform surgery through a patient's mouth, other natural orifice, or single incision, reducing or eliminating the need for external incisions into the abdomen. Operating through the body's natural orifices offers promise for less pain, shorter hospital stays, reduced risk of wound infection and no external scars -- and is rapidly becoming an option demanded by patients and healthcare providers. It has been estimated that over 4 million procedures currently performed using invasive means can be addressed with an incisionless approach in the future, creating a $5 billion opportunity for USGI.

http://www.usgimedical.com

USGI Endosurgical Operating System(TM)

USGI's Endosurgical Operating System(TM) (EOS) is designed to provide surgeons and gastroenterologists the tools they need to convert current operations to incisionless procedures. The system:
-- Facilitates access and visualization of the operating field via the

body's natural orifices

-- Provides a stable operating platform to enhance surgical precision and

control

-- Allows the use of multiple, robust instruments much like in

laparoscopy

-- Enables rapid, durable suturing and wound closure

The EOS includes the TransPort(TM) Multi-lumen Operating Platform, the g-Prox(R) Tissue Grasper and Approximation Device, expandable tissue anchors, and a variety of specialized instruments, all of which have received U.S. Food and Drug Administration (FDA) 510(k) clearance. To date, the EOS has been used in over 100 incisionless procedures in the U.S.

USGI Contacts:

Investors:

Eugene Chen, CEO

USGI Medical

949-369-3890

Fern Lazar

Lazar Partners

flazar@lazarpartners.com

+1-212-867-1765

Hollister Hovey

Lazar Partners

hhovey@lazarpartners.com

+1-212-867-1765


'/>"/>
SOURCE USGI Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
3. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
4. Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth
5. BioMS Medical announces its intention to renew a normal course issuer bid
6. Dr. Amit Dhawan Promoted to Medical Director for The Mattson Jack Group
7. ATS Medical Expands Open Pivot Heart Valve Offerings
8. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
9. Globus Medical Announces Record 2nd Quarter 2007 Results
10. IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
11. China Medical Technologies Reports First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... N.C. (PRWEB) , ... June 27, 2016 , ... ... commercial operations for Amgen, will join the faculty of the University of ... as adjunct professor of strategy and entrepreneurship at UNC Kenan-Flagler, with a focus ...
(Date:6/24/2016)... on a range of subjects including policies, debt and investment ... Speaking at a lecture to the Canadian Economics ... the country,s inflation target, which is set by both the ... "In certain areas there needs to be frequent ... not sit down and address strategy together?" He ...
(Date:6/24/2016)... NC (PRWEB) , ... June 24, 2016 , ... Researchers ... the most commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings are ... to read it now. , Diagnostic biomarkers are signposts in the blood, lung ...
(Date:6/23/2016)... Mass. , June 23, 2016   ... development of novel compounds designed to target cancer ... napabucasin, has been granted Orphan Drug Designation from ... the treatment of gastric cancer, including gastroesophageal junction ... stemness inhibitor designed to inhibit cancer stemness pathways ...
Breaking Biology Technology:
(Date:6/3/2016)... , June 3, 2016 ... von Nepal hat ... Lieferung hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, Registrierung ... in der Produktion und Implementierung von Identitätsmanagementlösungen. ... Ausschreibung im Januar teilgenommen, aber Decatur wurde ...
(Date:6/2/2016)... --  The Weather Company , an IBM Business (NYSE: ... in which consumers will be able to interact with IBM ... voice or text and receive relevant information about the product ... have long sought an advertising solution that can create a ... and valuable; and can scale across millions of interactions and ...
(Date:6/1/2016)... June 1, 2016 Favorable Government ... Administration and Criminal Identification to Boost Global Biometrics System ... released TechSci Research report, " Global Biometrics Market ... Forecast and Opportunities, 2011 - 2021", the global biometrics ... 2021, on account of growing security concerns across various ...
Breaking Biology News(10 mins):